Knowledge Diagram Navigation:

Spatial co-ordinations are initially random, and will automatically re-arrange to minimize complexity based on distance between relationships. Mouse down and drag to pan. Right click on the strategic diagram toggles between motion and stationary. Hover over abstract node (orange) to view abstractions. Hover over leaf node to view corresponding narrative. Left click on the leaf node expands the narrative to view full text.

Narrative Analysis - Report

Key Focus

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance. . Novo Nordisk and Eli Lilly have long dominated the rapidly growing weight loss drug market, but their duopoly is closer than ever to facing a threat from a new rival. ...

Amgen's drug, MariTide, is taken less frequently than Novo Nordisk's Wegovy and Eli Lilly's Zepbound, and may cause longer-lasting weight loss than the market leaders'injections. ...

No momentum supporting factor found

Challenge supporting factors

(drug,company,targets)

(company,targets,glp-1,orforglipron)

(company,targets,orforglipron)

(drug,company,orforglipron)

(drug,glp-1,orforglipron)

(drug,glp-1,targets,orforglipron)

(drug,targets,orforglipron)

(company,targets,eli)

(company,targets,glp-1,eli)

(drug,glp-1,targets,eli)

(drug,targets,eli)

(drug,glp-1,targets,company)

(drug,phipps)

(drug,mid-stage,survodutide)

(drug,mid-stage,positive)

Work-in-progress supporting factors

(drug,eli_lilly,market)

(drug,eli_lilly,novo_nordisk,market)

(drug,loss,novo_nordisk,eli_lilly,market)

(drug,loss,novo_nordisk,market)

(drug,maritide,phipps)

(drug,market,novo_nordisk)

(loss,market,novo_nordisk)

(drug,loss,market,eli_lilly)

(drug,loss,maritide,vomiting)

(drug,loss,vomiting)

(loss,phipps,nausea)

(drug,maritide,vomiting)

(loss,phipps,vomiting)

(loss,treatments,vomiting)

(loss,vomiting)

Time Period	Challenge	Momentum	WIP
Report	7.06	0.00	92.94

High Level Abstraction (HLA) combined

High Level Abstraction (HLA)	Report
(1) (drug,eli_lilly,market)	100.00
(2) (drug,eli_lilly,novo_nordisk,market)	98.67
(3) (drug,loss,novo_nordisk,eli_lilly,market)	97.10
(4) (drug,loss,novo_nordisk,market)	95.55
(5) (drug,maritide,phipps)	80.34
(6) (drug,market,novo_nordisk)	73.81
(7) (loss,market,novo_nordisk)	73.41
(8) (drug,loss,market,eli_lilly)	69.44
(9) (drug,loss,maritide,vomiting)	66.56
(10) (drug,loss,vomiting)	65.76
(11) (loss,phipps,nausea)	65.71
(12) (drug,maritide,vomiting)	65.49
(13) (loss,phipps,vomiting)	65.39
(14) (loss,treatments,vomiting)	65.36
(15) (loss,vomiting)	65.33
(16) (drug,loss,maritide,treatments)	65.15
(17) (drug,loss,treatments)	64.38
(18) (drug,maritide,treatments)	64.08
(19) (loss,phipps,treatments)	63.98
(20) (drug,loss,maritide,stop)	63.79
(21) (loss,maritide,market)	63.04
(22) (drug,loss,stop)	63.02
(23) (drug,maritide,stop)	62.72
(24) (loss,phipps,stop)	62.62
(25) (loss,treatments,stop)	62.54
(26) (drug,loss,maritide,phipps)	62.40
(27) (loss,nausea)	61.87
(28) (drug,loss,phipps)	61.63
(29) (drug,loss,maritide,novo_nordisk)	61.07
(30) (loss,maritide,novo_nordisk)	60.41
(31) (drug,loss,maritide,nausea)	60.14
(32) (drug,maritide,nausea)	59.58
(33) (loss,treatments,nausea)	59.18
(34) (drug,loss,maritide,market)	57.85
(35) (drug,maritide,market)	55.80
(36) (drug,eli_lilly,longer-lasting)	55.29
(37) (drug,eli_lilly,novo_nordisk,longer-lasting)	54.44
(38) (drug,loss,eli_lilly,longer-lasting)	53.72
(39) (drug,loss,maritide,longer-lasting)	53.00
(40) (drug,loss,market,longer-lasting)	52.62
(41) (drug,loss,novo_nordisk,eli_lilly,longer-lasting)	52.17
(42) (drug,loss,novo_nordisk,longer-lasting)	51.43
(43) (drug,maritide,longer-lasting)	51.19
(44) (drug,market,longer-lasting)	51.03
(45) (loss,eli_lilly,longer-lasting)	50.97
(46) (loss,eli_lilly,market,longer-lasting)	50.73
(47) (loss,maritide,longer-lasting)	50.44
(48) (loss,novo_nordisk,eli_lilly,longer-lasting)	50.15
(49) (loss,novo_nordisk,eli_lilly,market,longer-lasting)	49.96
(50) (loss,novo_nordisk,longer-lasting)	49.64
(51) (market,novo_nordisk,eli_lilly,longer-lasting)	49.51
(52) (market,novo_nordisk,longer-lasting)	49.45
(53) (drug,eli_lilly,novo_nordisk,leaders)	49.35
(54) (drug,loss,eli_lilly,leaders)	48.63
(55) (drug,company,targets)	48.41
(56) (drug,loss,maritide,leaders)	47.75
(57) (drug,loss,market,leaders)	47.32
(58) (drug,loss,novo_nordisk,eli_lilly,leaders)	46.92
(59) (drug,loss,novo_nordisk,leaders)	46.02
(60) (drug,maritide,leaders)	45.72
(61) (drug,market,leaders)	45.56
(62) (loss,eli_lilly,leaders)	45.51
(63) (loss,eli_lilly,market,leaders)	45.22
(64) (loss,maritide,leaders)	44.84
(65) (loss,novo_nordisk,eli_lilly,leaders)	44.52
(66) (loss,novo_nordisk,eli_lilly,market,leaders)	44.28
(67) (loss,novo_nordisk,leaders)	43.88
(68) (market,novo_nordisk,eli_lilly,leaders)	43.73
(69) (market,novo_nordisk,leaders)	43.67
(70) (drug,loss,maritide,eli_lilly)	43.38
(71) (loss,eli_lilly,maritide)	41.81
(72) (loss,eli_lilly,market,maritide)	41.17
(73) (loss,novo_nordisk,eli_lilly,maritide)	40.42
(74) (loss,novo_nordisk,eli_lilly,market,maritide)	39.89
(75) (drug,loss,novo_nordisk,eli_lilly,maritide)	38.77
(76) (drug,eli_lilly,manufacture)	36.53
(77) (drug,eli_lilly,novo_nordisk,manufacture)	35.86
(78) (drug,loss,eli_lilly,manufacture)	35.41
(79) (drug,late-stage,glp-1)	34.88
(80) (drug,loss,novo_nordisk,eli_lilly,manufacture)	34.56
(81) (drug,loss,novo_nordisk,manufacture)	33.97
(82) (loss,eli_lilly,manufacture)	33.49
(83) (loss,novo_nordisk,eli_lilly,manufacture)	33.28
(84) (loss,novo_nordisk,manufacture)	33.12
(85) (drug,loss,company)	33.04
(86) (drug,retatrutide)	32.56
(87) (drug,glp-1,targets,company)	32.56
(88) (drug,loss,market,company)	32.21
(89) (company,loss,twice-a-day)	31.25
(90) (company,twice-a-day)	31.23
(91) (drug,company,twice-a-day)	30.88
(92) (drug,loss,market,twice-a-day)	30.59
(93) (drug,loss,twice-a-day)	29.90
(94) (drug,market,twice-a-day)	29.71
(95) (market,company,twice-a-day)	29.52
(96) (market,twice-a-day)	29.44
(97) (company,loss,once-daily)	29.36
(98) (drug,company,once-daily)	29.10
(99) (drug,loss,market,once-daily)	28.67
(100) (drug,market,once-daily)	28.30

Supporting narratives:

Please refer to knowledge diagram for a complete set of supporting narratives.

challenge - Back to HLA

That combination appears to be even more effective at curbing a person's appetite.. . Eli Lilly is also developing an oral drug called orforglipron, which targets GLP-1. The company is slated to release late-stage trial data on the pill and retatrutide in 2025 ...
High Level Abstractions:

(company,targets,orforglipron)
(drug,company,orforglipron)
(drug,glp-1,targets,orforglipron)
(drug,targets,orforglipron)
(drug,targets,eli)
(company,targets,glp-1,orforglipron)
(drug,company,targets)
(company,targets,glp-1,eli)
(drug,glp-1,orforglipron)
(company,targets,eli)
(drug,glp-1,targets,eli)
Inferred entity relationships (33)
(drug,glp-1,late-stage) [inferred]
(drug,glp-1,retatrutide) [inferred]
(company,drug,loss,market) [inferred]
(company,drug,glp-1,targets) [inferred]
(company,drug,retatrutide) [inferred]
(company,drug,once-daily) [inferred]
(company,eli,targets) [inferred]
(company,drug,loss) [inferred]
(company,drug,therapies) [inferred]
(drug,glp-1,start) [inferred]
(drug,glp-1,survodutide) [inferred]
(drug,orforglipron,targets) [inferred]
(drug,glp-1,retatrutide,targets) [inferred]
(company,drug,market) [inferred]
(drug,glp-1,positive) [inferred]
(company,drug,twice-a-day) [inferred]
(company,eli,glp-1,targets) [inferred]
(company,drug,orforglipron) [inferred]
(company,drug,medical) [inferred]
(drug,glp-1,potential) [inferred]
(drug,glp-1,late-stage,targets) [inferred]
(drug,glp-1,zealand_pharma) [inferred]
(drug,glp-1,orforglipron) [inferred]
(drug,eli,targets) [inferred]
(drug,glp-1,orforglipron,targets) [inferred]
(company,drug,shots) [inferred]
(drug,glp-1,ingelheim) [inferred]
(drug,glp-1,loss) [inferred]
(company,glp-1,retatrutide,targets) [inferred]
(company,glp-1,late-stage,targets) [inferred]
(drug,eli,glp-1,targets) [inferred]
(company,drug,targets) [inferred]
(company,drug,late-stage) [inferred]

challenge - Back to HLA

That combination appears to be even more effective at curbing a person's appetite.. . Eli Lilly is also developing an oral drug called orforglipron, which targets GLP-1. The company is slated to release late-stage trial data on the pill and retatrutide in 2025. ...
High Level Abstractions:

(drug,glp-1,targets,company)
Inferred entity relationships (25)
(drug,glp-1,late-stage) [inferred]
(drug,glp-1,retatrutide) [inferred]
(company,drug,loss,market) [inferred]
(company,drug,retatrutide) [inferred]
(company,drug,once-daily) [inferred]
(company,drug,loss) [inferred]
(company,drug,therapies) [inferred]
(drug,glp-1,start) [inferred]
(drug,glp-1,survodutide) [inferred]
(drug,glp-1,retatrutide,targets) [inferred]
(company,drug,market) [inferred]
(drug,glp-1,positive) [inferred]
(company,drug,twice-a-day) [inferred]
(company,drug,orforglipron) [inferred]
(company,drug,medical) [inferred]
(drug,glp-1,potential) [inferred]
(drug,glp-1,late-stage,targets) [inferred]
(drug,glp-1,zealand_pharma) [inferred]
(drug,glp-1,orforglipron) [inferred]
(drug,glp-1,orforglipron,targets) [inferred]
(company,drug,shots) [inferred]
(drug,glp-1,ingelheim) [inferred]
(drug,glp-1,loss) [inferred]
(company,drug,targets) [inferred]
(company,drug,late-stage) [inferred]

challenge - Back to HLA

Less frequent doses of MariTide may also cause fewer side effects than other weight loss treatments, Phipps noted. Many patients stop taking existing drugs due to nausea and vomiting.. . MariTide causes some of those same side effects, but Phipps said a monthly or quarterly injection of the drug would lead to fewer days of feeling sick compared with a weekly dose ...
High Level Abstractions:

(drug,phipps)

challenge - Back to HLA

. In February, the companies also posted positive mid-stage trial data on survodutide in patients with a severe form of liver disease. ...
High Level Abstractions:

(drug,mid-stage,positive)
(drug,mid-stage,survodutide)
Inferred entity relationships (2)
(drug,mid-stage,survodutide) [inferred]
(drug,mid-stage,positive) [inferred]

challenge - Back to HLA

In February, the companies also posted positive mid-stage trial data on survodutide in patients with a severe form of liver disease. ...
High Level Abstractions:

(drug,mid-stage,liver)
(drug,mid-stage,disease)
Inferred entity relationships (2)
(drug,mid-stage,survodutide) [inferred]
(drug,mid-stage,positive) [inferred]

challenge - Back to HLA

A mid-stage trial found patients who are overweight or have obesity lost up to 19% of their weight after 46 weeks of treatment with the drug.. . In February, the companies also posted positive mid-stage trial data on survodutide in patients with a severe form of liver disease. ...
High Level Abstractions:

(drug,survodutide)

challenge - Back to HLA

Novo Nordisk and Eli Lilly are developing new drugs for weight loss and diabetes that could improve on their current treatments and enter the market earlier than MariTide and other experimental medicines. ...
High Level Abstractions:

(loss,market,treatments)
(loss,eli_lilly,maritide)
(loss,maritide,market)
(loss,novo_nordisk,eli_lilly,market,maritide)
(loss,eli_lilly,market,maritide)
(market,novo_nordisk,maritide)
(loss,novo_nordisk,eli_lilly,maritide)
(loss,maritide,treatments)
(market,novo_nordisk,eli_lilly,maritide)
Inferred entity relationships (15)
(eli_lilly,loss,maritide,market,novo_nordisk) [inferred]
(loss,market,pharmaceutical) [inferred]
(eli_lilly,loss,manufacture) [inferred]
(eli_lilly,loss,maritide) [inferred]
(loss,maritide,shots) [inferred]
(loss,maritide,novo_nordisk) [inferred]
(eli_lilly,loss,maritide,novo_nordisk) [inferred]
(loss,maritide,phipps) [inferred]
(loss,market,novo_nordisk) [inferred]
(loss,maritide,treatments) [inferred]
(maritide,market,novo_nordisk) [inferred]
(loss,market,once-daily) [inferred]
(loss,maritide,market) [inferred]
(eli_lilly,loss,manufacture,novo_nordisk) [inferred]
(eli_lilly,loss,maritide,market) [inferred]

challenge - Back to HLA

Viking will likely conduct another phase two trial that could last six to nine months, the company's CEO Brian Lian said during an investor call in March. Viking's treatment likely won't reach the market until 2029 or later, Jefferies analyst Akash Tewari wrote in a note that same month.. . Also in March, Viking said it plans to start a phase two trial on an oral version of its drug after it showed positive results in a small study ...
High Level Abstractions:

(market,analyst)

WIP - Back to HLA

Less frequent doses of MariTide may also cause fewer side effects than other weight loss treatments, Phipps noted. Many patients stop taking existing drugs due to nausea and vomiting. ...
High Level Abstractions:

(drug,maritide,treatments)
(loss,nausea)
(loss,treatments,stop)
(drug,loss,maritide,phipps)
(drug,maritide,phipps)
(drug,loss,phipps)
(drug,loss,maritide,nausea)
(drug,loss,maritide,vomiting)
(drug,maritide,vomiting)
(drug,loss,vomiting)
(drug,loss,treatments)
(loss,phipps,vomiting)
(drug,loss,stop)
(loss,phipps,stop)
(drug,loss,maritide,stop)
(drug,maritide,nausea)
(drug,maritide,stop)
(loss,phipps,treatments)
(loss,phipps,nausea)
(loss,treatments,nausea)
(drug,loss,maritide,treatments)
(loss,treatments,vomiting)
(loss,vomiting)
Inferred entity relationships (40)
(drug,loss,maritide,novo_nordisk) [inferred]
(drug,maritide,quarterly) [inferred]
(loss,treatments,vomiting) [inferred]
(loss,vomiting) [inferred]
(loss,maritide,shots) [inferred]
(loss,phipps,stop) [inferred]
(loss,stop,treatments) [inferred]
(drug,loss,maritide,nausea) [inferred]
(drug,loss,vomiting) [inferred]
(drug,loss,twice-a-day) [inferred]
(loss,phipps,treatments) [inferred]
(drug,loss,maritide,treatments) [inferred]
(loss,nausea,treatments) [inferred]
(loss,nausea) [inferred]
(drug,maritide,nausea) [inferred]
(loss,phipps,quarterly) [inferred]
(drug,loss,manufacture,novo_nordisk) [inferred]
(drug,loss,treatments) [inferred]
(loss,maritide,treatments) [inferred]
(loss,nausea,phipps) [inferred]
(drug,loss,market,twice-a-day) [inferred]
(loss,maritide,market) [inferred]
(drug,loss,market,once-daily) [inferred]
(drug,maritide,phipps) [inferred]
(drug,maritide,treatments) [inferred]
(drug,loss,market,novo_nordisk) [inferred]
(drug,maritide,vomiting) [inferred]
(drug,loss,maritide,phipps) [inferred]
(drug,maritide,novo_nordisk) [inferred]
(drug,loss,maritide,stop) [inferred]
(drug,loss,stop) [inferred]
(loss,phipps,vomiting) [inferred]
(loss,maritide,novo_nordisk) [inferred]
(drug,maritide,market) [inferred]
(drug,loss,maritide,market) [inferred]
(drug,loss,zealand_pharma) [inferred]
(drug,maritide,stop) [inferred]
(loss,maritide,phipps) [inferred]
(drug,loss,maritide,vomiting) [inferred]
(drug,loss,phipps) [inferred]

WIP - Back to HLA

Amgen's drug, MariTide, is taken less frequently than Novo Nordisk's Wegovy and Eli Lilly's Zepbound, and may cause longer-lasting weight loss than the market leaders'injections ...
High Level Abstractions:

(loss,novo_nordisk,eli_lilly,market,maritide)
(loss,eli_lilly,market,maritide)
(loss,maritide,novo_nordisk)
(loss,novo_nordisk,eli_lilly,maritide)
(loss,market,novo_nordisk)
(drug,loss,novo_nordisk,eli_lilly,maritide)
(drug,loss,maritide,novo_nordisk)
(loss,eli_lilly,maritide)
(drug,loss,market,eli_lilly)
(drug,market,novo_nordisk)
(drug,loss,maritide,eli_lilly)
Inferred entity relationships (60)
(eli_lilly,loss,maritide,market,novo_nordisk) [inferred]
(drug,eli_lilly,loss,manufacture) [inferred]
(loss,market,pharmaceutical) [inferred]
(loss,maritide,shots) [inferred]
(drug,eli_lilly,retatrutide) [inferred]
(drug,eli_lilly,mid-stage) [inferred]
(drug,loss,maritide,nausea) [inferred]
(loss,market,treatments) [inferred]
(drug,loss,vomiting) [inferred]
(drug,loss,twice-a-day) [inferred]
(drug,eli_lilly,leaders,loss,novo_nordisk) [inferred]
(drug,loss,maritide,treatments) [inferred]
(drug,eli_lilly,loss,maritide) [inferred]
(drug,market,start) [inferred]
(drug,eli_lilly,loss,maritide,novo_nordisk) [inferred]
(drug,market,once-daily) [inferred]
(drug,eli_lilly,loss,market,novo_nordisk) [inferred]
(eli_lilly,loss,maritide,novo_nordisk) [inferred]
(drug,loss,manufacture,novo_nordisk) [inferred]
(drug,loss,treatments) [inferred]
(drug,eli_lilly,novo) [inferred]
(loss,maritide,treatments) [inferred]
(drug,eli_lilly,longer-lasting,loss,novo_nordisk) [inferred]
(drug,loss,market,twice-a-day) [inferred]
(drug,market,twice-a-day) [inferred]
(drug,eli_lilly,longer-lasting,loss) [inferred]
(loss,maritide,market) [inferred]
(drug,eli_lilly,loss,market) [inferred]
(drug,loss,market,once-daily) [inferred]
(eli_lilly,loss,maritide,market) [inferred]
(drug,eli_lilly,leaders,loss) [inferred]
(drug,loss,market,novo_nordisk) [inferred]
(drug,loss,maritide,phipps) [inferred]
(drug,eli_lilly,leaders,novo_nordisk) [inferred]
(drug,eli_lilly,nordisk) [inferred]
(eli_lilly,loss,manufacture) [inferred]
(eli_lilly,loss,maritide) [inferred]
(drug,loss,maritide,stop) [inferred]
(drug,eli_lilly,loss,manufacture,novo_nordisk) [inferred]
(drug,loss,stop) [inferred]
(drug,eli_lilly,maritide) [inferred]
(drug,eli_lilly,market,novo_nordisk) [inferred]
(drug,eli_lilly,late-stage) [inferred]
(loss,maritide,novo_nordisk) [inferred]
(drug,loss,maritide,market) [inferred]
(drug,loss,zealand_pharma) [inferred]
(drug,eli_lilly,maritide,novo_nordisk) [inferred]
(drug,eli_lilly,market) [inferred]
(drug,eli_lilly,manufacture,novo_nordisk) [inferred]
(drug,loss,maritide,vomiting) [inferred]
(loss,maritide,phipps) [inferred]
(loss,market,novo_nordisk) [inferred]
(drug,loss,phipps) [inferred]
(maritide,market,novo_nordisk) [inferred]
(loss,market,once-daily) [inferred]
(drug,eli_lilly,longer-lasting) [inferred]
(drug,market,positive) [inferred]
(drug,eli_lilly,longer-lasting,novo_nordisk) [inferred]
(drug,eli_lilly,manufacture) [inferred]
(eli_lilly,loss,manufacture,novo_nordisk) [inferred]

WIP - Back to HLA

Amgen's drug, MariTide, is taken less frequently than Novo Nordisk's Wegovy and Eli Lilly's Zepbound, and may cause longer-lasting weight loss than the market leaders'injections. ...
High Level Abstractions:

(drug,loss,market,leaders)
(market,novo_nordisk,eli_lilly,leaders)
(drug,loss,novo_nordisk,market)
(drug,loss,maritide,market)
(loss,maritide,market)
(loss,novo_nordisk,eli_lilly,market,longer-lasting)
(drug,loss,novo_nordisk,eli_lilly,market)
(drug,loss,novo_nordisk,longer-lasting)
(market,novo_nordisk,longer-lasting)
(drug,maritide,leaders)
(drug,eli_lilly,market)
(loss,novo_nordisk,eli_lilly,leaders)
(loss,novo_nordisk,leaders)
(drug,loss,eli_lilly,longer-lasting)
(drug,loss,novo_nordisk,eli_lilly,leaders)
(drug,loss,maritide,leaders)
(drug,eli_lilly,novo_nordisk,leaders)
(market,novo_nordisk,leaders)
(drug,market,longer-lasting)
(drug,loss,novo_nordisk,eli_lilly,longer-lasting)
(drug,maritide,market)
(loss,novo_nordisk,longer-lasting)
(loss,eli_lilly,leaders)
(drug,loss,maritide,longer-lasting)
(loss,eli_lilly,market,leaders)
(loss,maritide,leaders)
(drug,market,leaders)
(loss,eli_lilly,market,longer-lasting)
(loss,novo_nordisk,eli_lilly,longer-lasting)
(loss,novo_nordisk,eli_lilly,market,leaders)
(drug,eli_lilly,novo_nordisk,longer-lasting)
(market,novo_nordisk,eli_lilly,longer-lasting)
(drug,eli_lilly,novo_nordisk,market)
(drug,loss,novo_nordisk,leaders)
(loss,eli_lilly,longer-lasting)
(drug,loss,eli_lilly,leaders)
(loss,maritide,longer-lasting)
(drug,maritide,longer-lasting)
(drug,eli_lilly,longer-lasting)
(drug,loss,market,longer-lasting)
Inferred entity relationships (94)
(drug,loss,maritide,novo_nordisk) [inferred]
(drug,maritide,quarterly) [inferred]
(eli_lilly,loss,maritide,market,novo_nordisk) [inferred]
(drug,eli_lilly,loss,manufacture) [inferred]
(leaders,market,novo_nordisk) [inferred]
(leaders,loss) [inferred]
(eli_lilly,longer-lasting,loss,market,novo_nordisk) [inferred]
(eli_lilly,leaders,loss,novo_nordisk) [inferred]
(drug,eli_lilly,retatrutide) [inferred]
(drug,loss,maritide,nausea) [inferred]
(drug,leaders,loss,market) [inferred]
(drug,eli_lilly,leaders,loss,novo_nordisk) [inferred]
(drug,loss,twice-a-day) [inferred]
(drug,eli_lilly,loss,maritide) [inferred]
(drug,eli_lilly,loss,maritide,novo_nordisk) [inferred]
(drug,maritide,nausea) [inferred]
(eli_lilly,leaders,market,novo_nordisk) [inferred]
(leaders,loss,novo_nordisk) [inferred]
(eli_lilly,longer-lasting,loss,market) [inferred]
(drug,eli_lilly,longer-lasting,loss,novo_nordisk) [inferred]
(eli_lilly,leaders,loss) [inferred]
(eli_lilly,leaders,loss,market,novo_nordisk) [inferred]
(drug,eli_lilly,longer-lasting,loss) [inferred]
(drug,eli_lilly,loss,market) [inferred]
(loss,maritide,market) [inferred]
(drug,loss,market,once-daily) [inferred]
(eli_lilly,loss,maritide,market) [inferred]
(drug,maritide,treatments) [inferred]
(drug,loss,market,novo_nordisk) [inferred]
(drug,maritide,vomiting) [inferred]
(drug,loss,maritide,phipps) [inferred]
(drug,maritide,novo_nordisk) [inferred]
(eli_lilly,longer-lasting,loss) [inferred]
(eli_lilly,loss,maritide) [inferred]
(drug,loss,maritide,stop) [inferred]
(drug,eli_lilly,loss,manufacture,novo_nordisk) [inferred]
(longer-lasting,loss,maritide) [inferred]
(drug,eli_lilly,market,novo_nordisk) [inferred]
(drug,eli_lilly,late-stage) [inferred]
(loss,maritide,novo_nordisk) [inferred]
(eli_lilly,longer-lasting,market,novo_nordisk) [inferred]
(drug,loss,zealand_pharma) [inferred]
(drug,maritide,stop) [inferred]
(drug,eli_lilly,maritide,novo_nordisk) [inferred]
(drug,eli_lilly,market) [inferred]
(drug,eli_lilly,manufacture,novo_nordisk) [inferred]
(drug,loss,maritide,vomiting) [inferred]
(drug,leaders,maritide) [inferred]
(loss,market,novo_nordisk) [inferred]
(maritide,market,novo_nordisk) [inferred]
(longer-lasting,loss,novo_nordisk) [inferred]
(drug,eli_lilly,longer-lasting) [inferred]
(drug,longer-lasting,maritide) [inferred]
(drug,eli_lilly,longer-lasting,novo_nordisk) [inferred]
(drug,longer-lasting,loss,market) [inferred]
(loss,market,pharmaceutical) [inferred]
(drug,longer-lasting,market) [inferred]
(eli_lilly,longer-lasting,loss,novo_nordisk) [inferred]
(loss,maritide,shots) [inferred]
(drug,eli_lilly,mid-stage) [inferred]
(loss,market,treatments) [inferred]
(drug,loss,vomiting) [inferred]
(drug,loss,maritide,treatments) [inferred]
(longer-lasting,loss,market) [inferred]
(drug,eli_lilly,loss,market,novo_nordisk) [inferred]
(eli_lilly,loss,maritide,novo_nordisk) [inferred]
(drug,loss,manufacture,novo_nordisk) [inferred]
(drug,eli_lilly,novo) [inferred]
(drug,loss,treatments) [inferred]
(drug,leaders,market) [inferred]
(loss,maritide,treatments) [inferred]
(drug,loss,market,twice-a-day) [inferred]
(eli_lilly,leaders,loss,market) [inferred]
(drug,maritide,phipps) [inferred]
(leaders,loss,treatments) [inferred]
(drug,eli_lilly,leaders,loss) [inferred]
(drug,eli_lilly,leaders,novo_nordisk) [inferred]
(drug,leaders,loss,novo_nordisk) [inferred]
(drug,eli_lilly,nordisk) [inferred]
(eli_lilly,loss,manufacture) [inferred]
(drug,loss,stop) [inferred]
(drug,eli_lilly,maritide) [inferred]
(leaders,loss,market) [inferred]
(drug,longer-lasting,loss,novo_nordisk) [inferred]
(longer-lasting,market,novo_nordisk) [inferred]
(drug,loss,maritide,market) [inferred]
(leaders,loss,maritide) [inferred]
(loss,maritide,phipps) [inferred]
(drug,longer-lasting,loss,maritide) [inferred]
(drug,loss,phipps) [inferred]
(loss,market,once-daily) [inferred]
(drug,leaders,loss,maritide) [inferred]
(drug,eli_lilly,manufacture) [inferred]
(eli_lilly,loss,manufacture,novo_nordisk) [inferred]

WIP - Back to HLA

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance. . Novo Nordisk and Eli Lilly have long dominated the rapidly growing weight loss drug market, but their duopoly is closer than ever to facing a threat from a new rival. ...
High Level Abstractions:

(drug,loss,novo_nordisk,market)
(drug,loss,novo_nordisk,eli_lilly,market)
(drug,eli_lilly,market)
(drug,eli_lilly,novo_nordisk,market)
Inferred entity relationships (50)
(drug,loss,maritide,novo_nordisk) [inferred]
(eli_lilly,loss,maritide,market,novo_nordisk) [inferred]
(drug,eli_lilly,loss,manufacture) [inferred]
(loss,market,pharmaceutical) [inferred]
(drug,eli_lilly,retatrutide) [inferred]
(drug,eli_lilly,mid-stage) [inferred]
(loss,market,treatments) [inferred]
(drug,loss,maritide,nausea) [inferred]
(drug,loss,vomiting) [inferred]
(drug,eli_lilly,leaders,loss,novo_nordisk) [inferred]
(drug,loss,twice-a-day) [inferred]
(drug,loss,maritide,treatments) [inferred]
(drug,eli_lilly,loss,maritide) [inferred]
(drug,eli_lilly,loss,maritide,novo_nordisk) [inferred]
(drug,eli_lilly,loss,market,novo_nordisk) [inferred]
(eli_lilly,loss,maritide,novo_nordisk) [inferred]
(drug,loss,manufacture,novo_nordisk) [inferred]
(drug,eli_lilly,novo) [inferred]
(drug,loss,treatments) [inferred]
(drug,eli_lilly,longer-lasting,loss,novo_nordisk) [inferred]
(drug,loss,market,twice-a-day) [inferred]
(drug,eli_lilly,longer-lasting,loss) [inferred]
(drug,eli_lilly,loss,market) [inferred]
(drug,loss,market,once-daily) [inferred]
(eli_lilly,loss,maritide,market) [inferred]
(drug,eli_lilly,leaders,loss) [inferred]
(drug,loss,maritide,phipps) [inferred]
(drug,eli_lilly,leaders,novo_nordisk) [inferred]
(drug,eli_lilly,nordisk) [inferred]
(eli_lilly,loss,manufacture) [inferred]
(eli_lilly,loss,maritide) [inferred]
(drug,loss,maritide,stop) [inferred]
(drug,eli_lilly,loss,manufacture,novo_nordisk) [inferred]
(drug,loss,stop) [inferred]
(drug,eli_lilly,maritide) [inferred]
(drug,eli_lilly,market,novo_nordisk) [inferred]
(drug,eli_lilly,late-stage) [inferred]
(drug,loss,maritide,market) [inferred]
(drug,loss,zealand_pharma) [inferred]
(drug,eli_lilly,maritide,novo_nordisk) [inferred]
(drug,eli_lilly,market) [inferred]
(drug,eli_lilly,manufacture,novo_nordisk) [inferred]
(drug,loss,maritide,vomiting) [inferred]
(loss,market,novo_nordisk) [inferred]
(drug,loss,phipps) [inferred]
(drug,eli_lilly,longer-lasting) [inferred]
(loss,market,once-daily) [inferred]
(drug,eli_lilly,longer-lasting,novo_nordisk) [inferred]
(drug,eli_lilly,manufacture) [inferred]
(eli_lilly,loss,manufacture,novo_nordisk) [inferred]

WIP - Back to HLA

That could make it easier for Amgen to manufacture enough supply - and avoid an issue that has been plaguing Novo Nordisk and Eli Lilly. ...
High Level Abstractions:

(drug,eli_lilly,manufacture)
(loss,eli_lilly,manufacture)
(drug,loss,novo_nordisk,eli_lilly,manufacture)
(drug,eli_lilly,novo_nordisk,manufacture)
(drug,loss,eli_lilly,manufacture)
(loss,novo_nordisk,eli_lilly,manufacture)
(drug,loss,novo_nordisk,manufacture)
(loss,novo_nordisk,manufacture)
Inferred entity relationships (47)
(drug,loss,maritide,novo_nordisk) [inferred]
(eli_lilly,loss,maritide,market,novo_nordisk) [inferred]
(drug,eli_lilly,loss,manufacture) [inferred]
(drug,eli_lilly,retatrutide) [inferred]
(drug,eli_lilly,mid-stage) [inferred]
(drug,loss,maritide,nausea) [inferred]
(drug,loss,vomiting) [inferred]
(drug,eli_lilly,leaders,loss,novo_nordisk) [inferred]
(drug,loss,twice-a-day) [inferred]
(drug,loss,maritide,treatments) [inferred]
(drug,eli_lilly,loss,maritide) [inferred]
(drug,eli_lilly,loss,maritide,novo_nordisk) [inferred]
(drug,eli_lilly,loss,market,novo_nordisk) [inferred]
(eli_lilly,loss,maritide,novo_nordisk) [inferred]
(drug,eli_lilly,novo) [inferred]
(drug,loss,treatments) [inferred]
(drug,eli_lilly,longer-lasting,loss,novo_nordisk) [inferred]
(loss,manufacture,novo_nordisk) [inferred]
(drug,loss,market,twice-a-day) [inferred]
(drug,eli_lilly,longer-lasting,loss) [inferred]
(drug,eli_lilly,loss,market) [inferred]
(drug,loss,market,once-daily) [inferred]
(eli_lilly,loss,maritide,market) [inferred]
(drug,eli_lilly,leaders,loss) [inferred]
(drug,loss,market,novo_nordisk) [inferred]
(drug,loss,maritide,phipps) [inferred]
(drug,eli_lilly,leaders,novo_nordisk) [inferred]
(drug,eli_lilly,nordisk) [inferred]
(eli_lilly,loss,manufacture) [inferred]
(eli_lilly,loss,maritide) [inferred]
(drug,loss,maritide,stop) [inferred]
(drug,eli_lilly,loss,manufacture,novo_nordisk) [inferred]
(drug,loss,stop) [inferred]
(drug,eli_lilly,maritide) [inferred]
(drug,eli_lilly,market,novo_nordisk) [inferred]
(drug,eli_lilly,late-stage) [inferred]
(drug,loss,maritide,market) [inferred]
(drug,loss,zealand_pharma) [inferred]
(drug,eli_lilly,maritide,novo_nordisk) [inferred]
(drug,eli_lilly,market) [inferred]
(drug,eli_lilly,manufacture,novo_nordisk) [inferred]
(drug,loss,maritide,vomiting) [inferred]
(drug,loss,phipps) [inferred]
(drug,eli_lilly,longer-lasting) [inferred]
(drug,eli_lilly,longer-lasting,novo_nordisk) [inferred]
(drug,eli_lilly,manufacture) [inferred]
(eli_lilly,loss,manufacture,novo_nordisk) [inferred]

WIP - Back to HLA

Meanwhile, investors are eager to see new data on Pfizer's once-daily obesity pill around the middle of the year, which will determine the company's fate in the weight loss drug market. The company scrapped the twice-a-day version of that pill, danuglipron, in December after patients had a difficult time tolerating it in a trial ...
High Level Abstractions:

(drug,market,twice-a-day)
(drug,company,twice-a-day)
(market,company,twice-a-day)
(drug,loss,market,twice-a-day)
(drug,loss,market,company)
(company,twice-a-day)
(drug,company,market)
(drug,loss,twice-a-day)
(market,twice-a-day)
(drug,loss,company)
(company,loss,twice-a-day)
Inferred entity relationships (51)
(drug,loss,maritide,novo_nordisk) [inferred]
(company,drug,loss,market) [inferred]
(loss,market,pharmaceutical) [inferred]
(company,drug,once-daily) [inferred]
(company,drug,therapies) [inferred]
(company,drug,loss) [inferred]
(company,drug,market) [inferred]
(drug,loss,maritide,nausea) [inferred]
(loss,market,treatments) [inferred]
(drug,loss,vomiting) [inferred]
(company,loss,shots) [inferred]
(company,market,rebound) [inferred]
(drug,loss,twice-a-day) [inferred]
(drug,loss,maritide,treatments) [inferred]
(drug,market,start) [inferred]
(drug,market,once-daily) [inferred]
(company,market,once-daily) [inferred]
(drug,loss,manufacture,novo_nordisk) [inferred]
(market,twice-a-day) [inferred]
(drug,loss,treatments) [inferred]
(company,loss,once-daily) [inferred]
(company,drug,shots) [inferred]
(drug,loss,market,twice-a-day) [inferred]
(drug,market,novo_nordisk) [inferred]
(drug,market,twice-a-day) [inferred]
(company,drug,targets) [inferred]
(company,market,nine) [inferred]
(drug,loss,market,once-daily) [inferred]
(drug,loss,market,novo_nordisk) [inferred]
(drug,loss,maritide,phipps) [inferred]
(company,market,novo_nordisk) [inferred]
(company,drug,glp-1,targets) [inferred]
(company,drug,retatrutide) [inferred]
(company,market,viking) [inferred]
(drug,loss,maritide,stop) [inferred]
(drug,loss,stop) [inferred]
(company,loss,market) [inferred]
(company,loss,treatments) [inferred]
(company,drug,twice-a-day) [inferred]
(company,drug,orforglipron) [inferred]
(company,drug,medical) [inferred]
(drug,loss,maritide,market) [inferred]
(drug,loss,zealand_pharma) [inferred]
(company,loss,maritide) [inferred]
(company,market,treatments) [inferred]
(drug,loss,maritide,vomiting) [inferred]
(loss,market,novo_nordisk) [inferred]
(drug,loss,phipps) [inferred]
(loss,market,once-daily) [inferred]
(drug,market,positive) [inferred]
(company,drug,late-stage) [inferred]

WIP - Back to HLA

Meanwhile, investors are eager to see new data on Pfizer's once-daily obesity pill around the middle of the year, which will determine the company's fate in the weight loss drug market ...
High Level Abstractions:

(company,loss,once-daily)
(loss,market,once-daily)
(drug,company,once-daily)
(market,company,once-daily)
(drug,market,once-daily)
(market,company,investors)
(drug,loss,market,once-daily)
(drug,loss,market,investors)
(loss,market,investors)
(company,loss,investors)
(market,once-daily)
Inferred entity relationships (51)
(drug,loss,maritide,novo_nordisk) [inferred]
(company,drug,loss,market) [inferred]
(loss,market,pharmaceutical) [inferred]
(company,market,twice-a-day) [inferred]
(company,drug,loss) [inferred]
(company,drug,therapies) [inferred]
(company,drug,market) [inferred]
(drug,loss,maritide,nausea) [inferred]
(loss,market,treatments) [inferred]
(drug,loss,vomiting) [inferred]
(company,loss,shots) [inferred]
(company,market,rebound) [inferred]
(drug,loss,twice-a-day) [inferred]
(drug,loss,maritide,treatments) [inferred]
(company,investors,market) [inferred]
(drug,market,start) [inferred]
(drug,loss,manufacture,novo_nordisk) [inferred]
(drug,loss,treatments) [inferred]
(company,loss,twice-a-day) [inferred]
(company,drug,shots) [inferred]
(drug,loss,market,twice-a-day) [inferred]
(market,once-daily) [inferred]
(drug,market,novo_nordisk) [inferred]
(drug,market,twice-a-day) [inferred]
(company,drug,targets) [inferred]
(company,market,nine) [inferred]
(drug,loss,market,novo_nordisk) [inferred]
(drug,loss,maritide,phipps) [inferred]
(company,market,novo_nordisk) [inferred]
(company,drug,glp-1,targets) [inferred]
(company,drug,retatrutide) [inferred]
(company,market,viking) [inferred]
(drug,loss,maritide,stop) [inferred]
(drug,loss,stop) [inferred]
(company,loss,market) [inferred]
(company,loss,treatments) [inferred]
(company,drug,twice-a-day) [inferred]
(company,drug,orforglipron) [inferred]
(company,drug,medical) [inferred]
(investors,loss,market) [inferred]
(drug,loss,maritide,market) [inferred]
(drug,loss,zealand_pharma) [inferred]
(company,loss,maritide) [inferred]
(company,market,treatments) [inferred]
(drug,loss,maritide,vomiting) [inferred]
(loss,market,novo_nordisk) [inferred]
(drug,loss,phipps) [inferred]
(loss,market,once-daily) [inferred]
(company,investors,loss) [inferred]
(drug,market,positive) [inferred]
(company,drug,late-stage) [inferred]

WIP - Back to HLA

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance. . Novo Nordisk and Eli Lilly have long dominated the rapidly growing weight loss drug market, but their duopoly is closer than ever to facing a threat from a new rival ...
High Level Abstractions:

(drug,loss,market,eli_lilly)
(drug,eli_lilly,nordisk)
(drug,eli_lilly,novo)
(drug,market,novo_nordisk)
(loss,market,novo_nordisk)
Inferred entity relationships (38)
(drug,eli_lilly,leaders,loss) [inferred]
(eli_lilly,loss,maritide,market,novo_nordisk) [inferred]
(drug,eli_lilly,loss,manufacture) [inferred]
(drug,eli_lilly,leaders,novo_nordisk) [inferred]
(loss,market,pharmaceutical) [inferred]
(drug,eli_lilly,nordisk) [inferred]
(eli_lilly,loss,manufacture) [inferred]
(eli_lilly,loss,maritide) [inferred]
(drug,eli_lilly,loss,manufacture,novo_nordisk) [inferred]
(drug,eli_lilly,retatrutide) [inferred]
(drug,eli_lilly,maritide) [inferred]
(drug,eli_lilly,market,novo_nordisk) [inferred]
(drug,eli_lilly,mid-stage) [inferred]
(drug,eli_lilly,late-stage) [inferred]
(loss,market,treatments) [inferred]
(drug,eli_lilly,leaders,loss,novo_nordisk) [inferred]
(drug,eli_lilly,loss,maritide) [inferred]
(drug,market,start) [inferred]
(drug,eli_lilly,loss,maritide,novo_nordisk) [inferred]
(drug,eli_lilly,maritide,novo_nordisk) [inferred]
(drug,market,once-daily) [inferred]
(drug,eli_lilly,loss,market,novo_nordisk) [inferred]
(drug,eli_lilly,market) [inferred]
(drug,eli_lilly,manufacture,novo_nordisk) [inferred]
(eli_lilly,loss,maritide,novo_nordisk) [inferred]
(drug,eli_lilly,novo) [inferred]
(loss,market,novo_nordisk) [inferred]
(drug,eli_lilly,longer-lasting,loss,novo_nordisk) [inferred]
(drug,eli_lilly,longer-lasting) [inferred]
(loss,market,once-daily) [inferred]
(drug,market,twice-a-day) [inferred]
(drug,eli_lilly,longer-lasting,loss) [inferred]
(drug,market,positive) [inferred]
(drug,eli_lilly,loss,market) [inferred]
(drug,eli_lilly,longer-lasting,novo_nordisk) [inferred]
(drug,eli_lilly,manufacture) [inferred]
(eli_lilly,loss,manufacture,novo_nordisk) [inferred]
(eli_lilly,loss,maritide,market) [inferred]

WIP - Back to HLA

Meanwhile, investors are eager to see new data on Pfizer's once-daily obesity pill around the middle of the year, which will determine the company's fate in the weight loss drug market. The company scrapped the twice-a-day version of that pill, danuglipron, in December after patients had a difficult time tolerating it in a trial. ...
High Level Abstractions:

(company,loss,danuglipron)
(drug,loss,market,danuglipron)
Inferred entity relationships (21)
(drug,loss,maritide,novo_nordisk) [inferred]
(drug,loss,twice-a-day) [inferred]
(drug,loss,maritide,treatments) [inferred]
(drug,loss,maritide,market) [inferred]
(drug,loss,market,novo_nordisk) [inferred]
(drug,loss,maritide,phipps) [inferred]
(drug,loss,zealand_pharma) [inferred]
(loss,market,pharmaceutical) [inferred]
(drug,loss,maritide,vomiting) [inferred]
(drug,loss,manufacture,novo_nordisk) [inferred]
(drug,loss,treatments) [inferred]
(loss,market,novo_nordisk) [inferred]
(drug,loss,phipps) [inferred]
(drug,loss,maritide,stop) [inferred]
(drug,loss,stop) [inferred]
(loss,market,once-daily) [inferred]
(drug,loss,market,twice-a-day) [inferred]
(drug,loss,maritide,nausea) [inferred]
(loss,market,treatments) [inferred]
(drug,loss,market,once-daily) [inferred]
(drug,loss,vomiting) [inferred]

WIP - Back to HLA

Among other potential entrants, Boehringer Ingelheim and Danish biotech firm Zealand Pharma are developing a weekly weight loss injection. The experimental drug works by targeting GLP-1 to suppress appetite and glucagon to increase energy expenditure ...
High Level Abstractions:

(drug,loss,zealand_pharma)
(drug,glp-1,loss)
(drug,glp-1,zealand_pharma)
(loss,zealand_pharma)
Inferred entity relationships (30)
(drug,glp-1,late-stage) [inferred]
(drug,loss,maritide,novo_nordisk) [inferred]
(drug,glp-1,retatrutide) [inferred]
(drug,loss,market,novo_nordisk) [inferred]
(drug,loss,maritide,phipps) [inferred]
(drug,glp-1,start) [inferred]
(drug,glp-1,survodutide) [inferred]
(drug,glp-1,retatrutide,targets) [inferred]
(drug,loss,maritide,stop) [inferred]
(drug,loss,stop) [inferred]
(drug,glp-1,positive) [inferred]
(drug,loss,maritide,nausea) [inferred]
(drug,loss,vomiting) [inferred]
(drug,loss,twice-a-day) [inferred]
(drug,glp-1,potential) [inferred]
(loss,zealand_pharma) [inferred]
(drug,loss,maritide,treatments) [inferred]
(drug,loss,maritide,market) [inferred]
(drug,glp-1,late-stage,targets) [inferred]
(drug,glp-1,zealand_pharma) [inferred]
(drug,glp-1,orforglipron) [inferred]
(drug,loss,maritide,vomiting) [inferred]
(drug,loss,manufacture,novo_nordisk) [inferred]
(drug,loss,treatments) [inferred]
(drug,glp-1,orforglipron,targets) [inferred]
(drug,loss,phipps) [inferred]
(drug,glp-1,ingelheim) [inferred]
(drug,glp-1,loss) [inferred]
(drug,loss,market,twice-a-day) [inferred]
(drug,loss,market,once-daily) [inferred]

WIP - Back to HLA

They added that the company's drug can also stick around in the body for much longer than current therapies. ...
High Level Abstractions:

(drug,company,therapies)
Inferred entity relationships (12)
(company,drug,orforglipron) [inferred]
(company,drug,medical) [inferred]
(company,drug,loss,market) [inferred]
(company,drug,glp-1,targets) [inferred]
(company,drug,retatrutide) [inferred]
(company,drug,once-daily) [inferred]
(company,drug,loss) [inferred]
(company,drug,shots) [inferred]
(company,drug,market) [inferred]
(company,drug,targets) [inferred]
(company,drug,late-stage) [inferred]
(company,drug,twice-a-day) [inferred]

WIP - Back to HLA

Also in an early-stage trial is AstraZeneca's experimental obesity drug AZD6234, which targets another gut hormone called amylin. The company hopes it can combine AZD6234 with its oral GLP-1 to help patients achieve greater weight loss than with existing drugs, AstraZeneca CEO Pascal Soriot said in November ...
High Level Abstractions:

(drug,company,targets)
(drug,targets,hormone)
(drug,targets,gut)
(drug,glp-1,targets,company)
Inferred entity relationships (26)
(drug,glp-1,late-stage) [inferred]
(drug,glp-1,retatrutide) [inferred]
(company,drug,loss,market) [inferred]
(company,drug,glp-1,targets) [inferred]
(company,drug,retatrutide) [inferred]
(company,drug,once-daily) [inferred]
(company,drug,loss) [inferred]
(company,drug,therapies) [inferred]
(drug,glp-1,start) [inferred]
(drug,glp-1,survodutide) [inferred]
(drug,glp-1,retatrutide,targets) [inferred]
(company,drug,market) [inferred]
(drug,glp-1,positive) [inferred]
(company,drug,twice-a-day) [inferred]
(company,drug,orforglipron) [inferred]
(company,drug,medical) [inferred]
(drug,glp-1,potential) [inferred]
(drug,glp-1,late-stage,targets) [inferred]
(drug,glp-1,zealand_pharma) [inferred]
(drug,glp-1,orforglipron) [inferred]
(drug,glp-1,orforglipron,targets) [inferred]
(company,drug,shots) [inferred]
(drug,glp-1,ingelheim) [inferred]
(drug,glp-1,loss) [inferred]
(company,drug,targets) [inferred]
(company,drug,late-stage) [inferred]

WIP - Back to HLA

MariTide showed sustained weight loss after a single injection or multiple shots during a phase one trial, which allowed for less frequent doses of the drug, according to the study authors ...
High Level Abstractions:

(company,shots)
(drug,company,shots)
(company,loss,shots)
Inferred entity relationships (17)
(company,drug,orforglipron) [inferred]
(company,drug,medical) [inferred]
(company,drug,loss,market) [inferred]
(company,loss,maritide) [inferred]
(company,drug,glp-1,targets) [inferred]
(company,drug,retatrutide) [inferred]
(company,drug,once-daily) [inferred]
(company,drug,loss) [inferred]
(company,drug,therapies) [inferred]
(company,loss,once-daily) [inferred]
(company,loss,twice-a-day) [inferred]
(company,drug,market) [inferred]
(company,loss,market) [inferred]
(company,loss,treatments) [inferred]
(company,drug,targets) [inferred]
(company,drug,late-stage) [inferred]
(company,drug,twice-a-day) [inferred]

WIP - Back to HLA

Eli Lilly is also developing an oral drug called orforglipron, which targets GLP-1. The company is slated to release late-stage trial data on the pill and retatrutide in 2025. ...
High Level Abstractions:

(drug,retatrutide)
(drug,glp-1,retatrutide)
(drug,targets,late-stage)
(drug,late-stage,glp-1)
(drug,company,late-stage)
(drug,glp-1,targets,retatrutide)
(company,targets,glp-1,late-stage)
(company,targets,glp-1,retatrutide)
(company,targets,late-stage)
(drug,targets,retatrutide)
(drug,glp-1,targets,late-stage)
(drug,company,retatrutide)
(company,targets,retatrutide)
Inferred entity relationships (34)
(drug,glp-1,late-stage) [inferred]
(drug,glp-1,retatrutide) [inferred]
(drug,retatrutide,targets) [inferred]
(company,drug,loss,market) [inferred]
(company,drug,glp-1,targets) [inferred]
(company,drug,retatrutide) [inferred]
(drug,late-stage,targets) [inferred]
(company,drug,once-daily) [inferred]
(company,drug,loss) [inferred]
(company,drug,therapies) [inferred]
(drug,glp-1,start) [inferred]
(drug,glp-1,survodutide) [inferred]
(drug,glp-1,retatrutide,targets) [inferred]
(company,glp-1,orforglipron,targets) [inferred]
(company,drug,market) [inferred]
(drug,glp-1,positive) [inferred]
(company,drug,twice-a-day) [inferred]
(company,drug,orforglipron) [inferred]
(company,drug,medical) [inferred]
(drug,glp-1,potential) [inferred]
(drug,glp-1,late-stage,targets) [inferred]
(company,retatrutide) [inferred]
(drug,glp-1,zealand_pharma) [inferred]
(drug,glp-1,orforglipron) [inferred]
(drug,late-stage,survodutide) [inferred]
(drug,retatrutide) [inferred]
(drug,glp-1,orforglipron,targets) [inferred]
(company,drug,shots) [inferred]
(drug,glp-1,ingelheim) [inferred]
(drug,glp-1,loss) [inferred]
(company,glp-1,retatrutide,targets) [inferred]
(company,glp-1,late-stage,targets) [inferred]
(company,drug,targets) [inferred]
(company,drug,late-stage) [inferred]

WIP - Back to HLA

The company has completed a phase one trial in patients with diabetes and plans to present the data at a medical conference later this year, executives said during an earnings call in April. ...
High Level Abstractions:

(drug,company,medical)
Inferred entity relationships (13)
(company,drug,orforglipron) [inferred]
(company,drug,loss,market) [inferred]
(company,drug,glp-1,targets) [inferred]
(company,drug,retatrutide) [inferred]
(company,drug,once-daily) [inferred]
(company,drug,loss) [inferred]
(company,drug,therapies) [inferred]
(company,drug,shots) [inferred]
(company,drug,market) [inferred]
(company,drug,targets) [inferred]
(company,drug,late-stage) [inferred]
(company,drug,twice-a-day) [inferred]
(drug,medical,targets) [inferred]

WIP - Back to HLA

. MariTide causes some of those same side effects, but Phipps said a monthly or quarterly injection of the drug would lead to fewer days of feeling sick compared with a weekly dose ...
High Level Abstractions:

(drug,maritide,phipps)
(drug,maritide,quarterly)
Inferred entity relationships (8)
(drug,maritide,quarterly) [inferred]
(drug,maritide,market) [inferred]
(drug,maritide,treatments) [inferred]
(drug,maritide,vomiting) [inferred]
(drug,maritide,novo_nordisk) [inferred]
(drug,maritide,stop) [inferred]
(drug,maritide,nausea) [inferred]
(drug,maritide,phipps) [inferred]

WIP - Back to HLA

. Amgen's drug, MariTide, is taken less frequently than Novo Nordisk's Wegovy and Eli Lilly's Zepbound, and may cause longer-lasting weight loss than the market leaders'injections ...
High Level Abstractions:

(drug,eli_lilly,maritide)
(drug,maritide,novo_nordisk)
(drug,eli_lilly,novo_nordisk,maritide)
Inferred entity relationships (32)
(drug,maritide,quarterly) [inferred]
(drug,eli_lilly,leaders,loss) [inferred]
(drug,maritide,treatments) [inferred]
(drug,maritide,vomiting) [inferred]
(drug,eli_lilly,loss,manufacture) [inferred]
(drug,eli_lilly,leaders,novo_nordisk) [inferred]
(eli_lilly,maritide,market,novo_nordisk) [inferred]
(drug,eli_lilly,nordisk) [inferred]
(drug,eli_lilly,loss,manufacture,novo_nordisk) [inferred]
(drug,eli_lilly,retatrutide) [inferred]
(drug,eli_lilly,market,novo_nordisk) [inferred]
(drug,eli_lilly,maritide) [inferred]
(drug,eli_lilly,mid-stage) [inferred]
(drug,eli_lilly,late-stage) [inferred]
(drug,eli_lilly,leaders,loss,novo_nordisk) [inferred]
(drug,maritide,market) [inferred]
(drug,eli_lilly,loss,maritide) [inferred]
(drug,maritide,stop) [inferred]
(drug,eli_lilly,loss,maritide,novo_nordisk) [inferred]
(drug,maritide,nausea) [inferred]
(drug,eli_lilly,maritide,novo_nordisk) [inferred]
(drug,eli_lilly,loss,market,novo_nordisk) [inferred]
(drug,eli_lilly,market) [inferred]
(drug,eli_lilly,manufacture,novo_nordisk) [inferred]
(drug,eli_lilly,novo) [inferred]
(drug,eli_lilly,longer-lasting,loss,novo_nordisk) [inferred]
(drug,eli_lilly,longer-lasting) [inferred]
(drug,eli_lilly,longer-lasting,loss) [inferred]
(drug,eli_lilly,loss,market) [inferred]
(drug,maritide,phipps) [inferred]
(drug,eli_lilly,longer-lasting,novo_nordisk) [inferred]
(drug,eli_lilly,manufacture) [inferred]

WIP - Back to HLA

The experimental drug works by targeting GLP-1 to suppress appetite and glucagon to increase energy expenditure. . . Boehringer Ingelheim in August said it was moving the drug, called survodutide, into a late-stage study. ...
High Level Abstractions:

(drug,glp-1,survodutide)
(drug,glp-1,ingelheim)
(drug,late-stage,ingelheim)
(drug,survodutide)
(drug,late-stage,survodutide)
Inferred entity relationships (14)
(drug,glp-1,late-stage) [inferred]
(drug,glp-1,potential) [inferred]
(drug,glp-1,retatrutide) [inferred]
(drug,glp-1,late-stage,targets) [inferred]
(drug,late-stage,targets) [inferred]
(drug,glp-1,zealand_pharma) [inferred]
(drug,glp-1,orforglipron) [inferred]
(drug,glp-1,start) [inferred]
(drug,glp-1,orforglipron,targets) [inferred]
(drug,glp-1,survodutide) [inferred]
(drug,glp-1,retatrutide,targets) [inferred]
(drug,glp-1,ingelheim) [inferred]
(drug,glp-1,loss) [inferred]
(drug,glp-1,positive) [inferred]

WIP - Back to HLA

The experimental drug works by targeting GLP-1 to suppress appetite and glucagon to increase energy expenditure. . . Boehringer Ingelheim in August said it was moving the drug, called survodutide, into a late-stage study ...
High Level Abstractions:

(drug,late-stage,glucagon)
(drug,late-stage,energy)
(drug,late-stage,glp-1)
(drug,late-stage,increase)
(drug,late-stage,boehringer)
Inferred entity relationships (14)
(drug,glp-1,potential) [inferred]
(drug,glp-1,retatrutide) [inferred]
(drug,glp-1,late-stage,targets) [inferred]
(drug,late-stage,targets) [inferred]
(drug,glp-1,zealand_pharma) [inferred]
(drug,glp-1,orforglipron) [inferred]
(drug,glp-1,start) [inferred]
(drug,late-stage,survodutide) [inferred]
(drug,glp-1,orforglipron,targets) [inferred]
(drug,glp-1,survodutide) [inferred]
(drug,glp-1,retatrutide,targets) [inferred]
(drug,glp-1,ingelheim) [inferred]
(drug,glp-1,loss) [inferred]
(drug,glp-1,positive) [inferred]

WIP - Back to HLA

Also in March, Viking said it plans to start a phase two trial on an oral version of its drug after it showed positive results in a small study. ...
High Level Abstractions:

(drug,market,positive)
(drug,glp-1,start)
(market,positive)
Inferred entity relationships (17)
(drug,glp-1,late-stage) [inferred]
(drug,glp-1,potential) [inferred]
(drug,glp-1,retatrutide) [inferred]
(drug,market,start) [inferred]
(drug,glp-1,late-stage,targets) [inferred]
(market,positive) [inferred]
(drug,glp-1,zealand_pharma) [inferred]
(drug,market,once-daily) [inferred]
(drug,glp-1,orforglipron) [inferred]
(drug,glp-1,orforglipron,targets) [inferred]
(drug,glp-1,survodutide) [inferred]
(drug,glp-1,retatrutide,targets) [inferred]
(drug,glp-1,ingelheim) [inferred]
(drug,glp-1,loss) [inferred]
(drug,glp-1,positive) [inferred]
(drug,market,novo_nordisk) [inferred]
(drug,market,twice-a-day) [inferred]

WIP - Back to HLA

Among other potential entrants, Boehringer Ingelheim and Danish biotech firm Zealand Pharma are developing a weekly weight loss injection ...
High Level Abstractions:

(drug,glp-1,potential)
Inferred entity relationships (12)
(drug,glp-1,late-stage) [inferred]
(drug,glp-1,retatrutide) [inferred]
(drug,glp-1,late-stage,targets) [inferred]
(drug,glp-1,zealand_pharma) [inferred]
(drug,glp-1,orforglipron) [inferred]
(drug,glp-1,start) [inferred]
(drug,glp-1,orforglipron,targets) [inferred]
(drug,glp-1,survodutide) [inferred]
(drug,glp-1,retatrutide,targets) [inferred]
(drug,glp-1,ingelheim) [inferred]
(drug,glp-1,loss) [inferred]
(drug,glp-1,positive) [inferred]

WIP - Back to HLA

Also in March, Viking said it plans to start a phase two trial on an oral version of its drug after it showed positive results in a small study.. . Structure Therapeutics is also developing an oral GLP-1 for obesity and diabetes ...
High Level Abstractions:

(drug,glp-1,positive)
Inferred entity relationships (12)
(drug,glp-1,late-stage) [inferred]
(drug,glp-1,potential) [inferred]
(drug,glp-1,retatrutide) [inferred]
(drug,glp-1,late-stage,targets) [inferred]
(drug,glp-1,zealand_pharma) [inferred]
(drug,glp-1,orforglipron) [inferred]
(drug,glp-1,start) [inferred]
(drug,glp-1,orforglipron,targets) [inferred]
(drug,glp-1,survodutide) [inferred]
(drug,glp-1,retatrutide,targets) [inferred]
(drug,glp-1,ingelheim) [inferred]
(drug,glp-1,loss) [inferred]

WIP - Back to HLA

Viking's treatment likely won't reach the market until 2029 or later, Jefferies analyst Akash Tewari wrote in a note that same month.. . Also in March, Viking said it plans to start a phase two trial on an oral version of its drug after it showed positive results in a small study ...
High Level Abstractions:

(drug,market,jefferies)
(drug,market,start)
(market,start)
Inferred entity relationships (5)
(market,start) [inferred]
(drug,market,novo_nordisk) [inferred]
(drug,market,twice-a-day) [inferred]
(drug,market,once-daily) [inferred]
(drug,market,positive) [inferred]

WIP - Back to HLA

. Meanwhile, Eli Lilly is studying an experimental drug called retatrutide in a late-stage trial. That treatment helped patients lose up to 24% of their weight after almost a year in a mid-stage trial, which set a new bar for weight loss ...
High Level Abstractions:

(drug,eli_lilly,late-stage)
Inferred entity relationships (23)
(drug,eli_lilly,leaders,loss) [inferred]
(drug,eli_lilly,loss,manufacture) [inferred]
(drug,eli_lilly,leaders,novo_nordisk) [inferred]
(drug,eli_lilly,nordisk) [inferred]
(drug,eli_lilly,loss,manufacture,novo_nordisk) [inferred]
(drug,eli_lilly,retatrutide) [inferred]
(drug,eli_lilly,maritide) [inferred]
(drug,eli_lilly,market,novo_nordisk) [inferred]
(drug,eli_lilly,mid-stage) [inferred]
(drug,eli_lilly,leaders,loss,novo_nordisk) [inferred]
(drug,eli_lilly,loss,maritide) [inferred]
(drug,eli_lilly,loss,maritide,novo_nordisk) [inferred]
(drug,eli_lilly,maritide,novo_nordisk) [inferred]
(drug,eli_lilly,loss,market,novo_nordisk) [inferred]
(drug,eli_lilly,market) [inferred]
(drug,eli_lilly,manufacture,novo_nordisk) [inferred]
(drug,eli_lilly,novo) [inferred]
(drug,eli_lilly,longer-lasting,loss,novo_nordisk) [inferred]
(drug,eli_lilly,longer-lasting) [inferred]
(drug,eli_lilly,longer-lasting,loss) [inferred]
(drug,eli_lilly,loss,market) [inferred]
(drug,eli_lilly,longer-lasting,novo_nordisk) [inferred]
(drug,eli_lilly,manufacture) [inferred]

WIP - Back to HLA

Novo Nordisk is studying CagriSema in six late-stage clinical trials and could release data from a 68-week study in obese patients later this year.. . Meanwhile, Eli Lilly is studying an experimental drug called retatrutide in a late-stage trial. That treatment helped patients lose up to 24% of their weight after almost a year in a mid-stage trial, which set a new bar for weight loss ...
High Level Abstractions:

(drug,retatrutide)
(drug,eli_lilly,retatrutide)
Inferred entity relationships (24)
(drug,eli_lilly,leaders,loss) [inferred]
(drug,retatrutide,targets) [inferred]
(drug,eli_lilly,loss,manufacture) [inferred]
(drug,eli_lilly,leaders,novo_nordisk) [inferred]
(drug,eli_lilly,nordisk) [inferred]
(drug,eli_lilly,loss,manufacture,novo_nordisk) [inferred]
(drug,eli_lilly,maritide) [inferred]
(drug,eli_lilly,market,novo_nordisk) [inferred]
(drug,eli_lilly,mid-stage) [inferred]
(drug,eli_lilly,late-stage) [inferred]
(drug,eli_lilly,leaders,loss,novo_nordisk) [inferred]
(drug,eli_lilly,loss,maritide) [inferred]
(drug,eli_lilly,loss,maritide,novo_nordisk) [inferred]
(drug,eli_lilly,maritide,novo_nordisk) [inferred]
(drug,eli_lilly,loss,market,novo_nordisk) [inferred]
(drug,eli_lilly,market) [inferred]
(drug,eli_lilly,manufacture,novo_nordisk) [inferred]
(drug,eli_lilly,novo) [inferred]
(drug,eli_lilly,longer-lasting,loss,novo_nordisk) [inferred]
(drug,eli_lilly,longer-lasting) [inferred]
(drug,eli_lilly,longer-lasting,loss) [inferred]
(drug,eli_lilly,loss,market) [inferred]
(drug,eli_lilly,longer-lasting,novo_nordisk) [inferred]
(drug,eli_lilly,manufacture) [inferred]

WIP - Back to HLA

Meanwhile, Eli Lilly is studying an experimental drug called retatrutide in a late-stage trial. That treatment helped patients lose up to 24% of their weight after almost a year in a mid-stage trial, which set a new bar for weight loss. ...
High Level Abstractions:

(drug,eli_lilly,mid-stage)
Inferred entity relationships (23)
(drug,eli_lilly,leaders,loss) [inferred]
(drug,eli_lilly,loss,manufacture) [inferred]
(drug,eli_lilly,leaders,novo_nordisk) [inferred]
(drug,eli_lilly,nordisk) [inferred]
(drug,eli_lilly,loss,manufacture,novo_nordisk) [inferred]
(drug,eli_lilly,retatrutide) [inferred]
(drug,eli_lilly,maritide) [inferred]
(drug,eli_lilly,market,novo_nordisk) [inferred]
(drug,eli_lilly,late-stage) [inferred]
(drug,eli_lilly,leaders,loss,novo_nordisk) [inferred]
(drug,eli_lilly,loss,maritide) [inferred]
(drug,eli_lilly,loss,maritide,novo_nordisk) [inferred]
(drug,eli_lilly,maritide,novo_nordisk) [inferred]
(drug,eli_lilly,loss,market,novo_nordisk) [inferred]
(drug,eli_lilly,market) [inferred]
(drug,eli_lilly,manufacture,novo_nordisk) [inferred]
(drug,eli_lilly,novo) [inferred]
(drug,eli_lilly,longer-lasting,loss,novo_nordisk) [inferred]
(drug,eli_lilly,longer-lasting) [inferred]
(drug,eli_lilly,longer-lasting,loss) [inferred]
(drug,eli_lilly,loss,market) [inferred]
(drug,eli_lilly,longer-lasting,novo_nordisk) [inferred]
(drug,eli_lilly,manufacture) [inferred]

WIP - Back to HLA

The company has completed a phase one trial in patients with diabetes and plans to present the data at a medical conference later this year, executives said during an earnings call in April.. . Also in an early-stage trial is AstraZeneca's experimental obesity drug AZD6234, which targets another gut hormone called amylin. The company hopes it can combine AZD6234 with its oral GLP-1 to help patients achieve greater weight loss than with existing drugs, AstraZeneca CEO Pascal Soriot said in November ...
High Level Abstractions:

(drug,targets,azd6234)

WIP - Back to HLA

The company has completed a phase one trial in patients with diabetes and plans to present the data at a medical conference later this year, executives said during an earnings call in April.. . Also in an early-stage trial is AstraZeneca's experimental obesity drug AZD6234, which targets another gut hormone called amylin ...
High Level Abstractions:

(drug,targets,earnings)
(drug,targets,medical)

WIP - Back to HLA

Amgen is already starting to expand manufacturing capacity for MariTide, executives said during an earnings call on May 2.. . Less frequent doses of MariTide may also cause fewer side effects than other weight loss treatments, Phipps noted. ...
High Level Abstractions:

(loss,maritide,treatments)
Inferred entity relationships (4)
(loss,maritide,shots) [inferred]
(loss,maritide,market) [inferred]
(loss,maritide,phipps) [inferred]
(loss,maritide,novo_nordisk) [inferred]

WIP - Back to HLA

Several drugmakers are developing weekly injections or daily pills, but some haven't ruled out testing less frequent dosing for their drugs. . . MariTide showed sustained weight loss after a single injection or multiple shots during a phase one trial, which allowed for less frequent doses of the drug, according to the study authors ...
High Level Abstractions:

(loss,maritide,shots)
Inferred entity relationships (4)
(loss,maritide,treatments) [inferred]
(loss,maritide,market) [inferred]
(loss,maritide,phipps) [inferred]
(loss,maritide,novo_nordisk) [inferred]

WIP - Back to HLA

Less frequent doses of MariTide may also cause fewer side effects than other weight loss treatments, Phipps noted. ...
High Level Abstractions:

(loss,maritide,phipps)
(loss,manufacturing,phipps)
Inferred entity relationships (7)
(loss,maritide,shots) [inferred]
(loss,maritide,treatments) [inferred]
(loss,manufacturing,maritide) [inferred]
(loss,manufacturing,market) [inferred]
(loss,maritide,market) [inferred]
(loss,manufacturing,treatments) [inferred]
(loss,maritide,novo_nordisk) [inferred]

WIP - Back to HLA

Amgen is already starting to expand manufacturing capacity for MariTide, executives said during an earnings call on May 2.. . Less frequent doses of MariTide may also cause fewer side effects than other weight loss treatments, Phipps noted ...
High Level Abstractions:

(loss,maritide,manufacturing)
(loss,maritide,expand)
(loss,treatments,expand)
(loss,manufacturing,expand)
(loss,treatments,earnings)
(loss,treatments,manufacturing)
(loss,manufacturing,earnings)
Inferred entity relationships (15)
(expand,loss,maritide) [inferred]
(loss,treatments,vomiting) [inferred]
(loss,manufacturing,maritide) [inferred]
(earnings,loss,manufacturing) [inferred]
(loss,manufacturing,phipps) [inferred]
(loss,maritide,phipps) [inferred]
(loss,maritide,shots) [inferred]
(loss,maritide,treatments) [inferred]
(earnings,loss,treatments) [inferred]
(loss,manufacturing,market) [inferred]
(expand,loss,treatments) [inferred]
(loss,maritide,market) [inferred]
(loss,manufacturing,treatments) [inferred]
(expand,loss,manufacturing) [inferred]
(loss,maritide,novo_nordisk) [inferred]

WIP - Back to HLA

Several drugmakers are developing weekly injections or daily pills, but some haven't ruled out testing less frequent dosing for their drugs ...
High Level Abstractions:

(loss,maritide,injections)
Inferred entity relationships (5)
(loss,maritide,shots) [inferred]
(loss,maritide,treatments) [inferred]
(loss,maritide,market) [inferred]
(loss,maritide,phipps) [inferred]
(loss,maritide,novo_nordisk) [inferred]

WIP - Back to HLA

"Even if you do have some nausea for the day, just once a quarter versus once a week I think that's huge for getting more patients to stay on," said Phipps ...
High Level Abstractions:

(loss,phipps,nausea)
Inferred entity relationships (2)
(loss,nausea,treatments) [inferred]
(loss,nausea) [inferred]

WIP - Back to HLA

MariTide causes some of those same side effects, but Phipps said a monthly or quarterly injection of the drug would lead to fewer days of feeling sick compared with a weekly dose ...
High Level Abstractions:

(loss,phipps,quarterly)
Inferred entity relationships (3)
(loss,phipps,treatments) [inferred]
(loss,phipps,stop) [inferred]
(loss,phipps,vomiting) [inferred]

WIP - Back to HLA

Amgen is among the leaders of a pack of drugmakers racing to join the market with their own weight loss treatments. As the company proceeds with the trials needed to bring its experimental obesity injection to the market in the coming years, it could see a few advantages ...
High Level Abstractions:

(company,loss,leaders)
(loss,treatments,company)
(loss,market,company)
(loss,market,treatments)
(company,treatments,market)
(company,treatments,leaders)
(loss,market,leaders)
(loss,treatments,leaders)
(loss,leaders)
Inferred entity relationships (24)
(leaders,loss,treatments) [inferred]
(loss,treatments,vomiting) [inferred]
(company,market,novo_nordisk) [inferred]
(loss,market,pharmaceutical) [inferred]
(company,leaders,loss) [inferred]
(company,market,viking) [inferred]
(company,market,twice-a-day) [inferred]
(leaders,loss) [inferred]
(leaders,loss,market) [inferred]
(company,loss,treatments) [inferred]
(company,loss,market) [inferred]
(loss,market,treatments) [inferred]
(company,loss,shots) [inferred]
(company,market,rebound) [inferred]
(company,loss,maritide) [inferred]
(company,leaders,treatments) [inferred]
(leaders,loss,maritide) [inferred]
(company,market,once-daily) [inferred]
(leaders,loss,novo_nordisk) [inferred]
(loss,market,novo_nordisk) [inferred]
(company,loss,once-daily) [inferred]
(company,loss,twice-a-day) [inferred]
(loss,market,once-daily) [inferred]
(company,market,nine) [inferred]

WIP - Back to HLA

Amgen's drug, MariTide, is taken less frequently than Novo Nordisk's Wegovy and Eli Lilly's Zepbound, and may cause longer-lasting weight loss than the market leaders'injections. Amgen, one of the nation's biggest pharmaceutical companies, can also produce drugs at scale - a huge edge over smaller biotech companies that lack a large manufacturing footprint ...
High Level Abstractions:

(loss,market,leaders)
(loss,market,pharmaceutical)
(loss,market,longer-lasting)
Inferred entity relationships (10)
(leaders,loss,treatments) [inferred]
(loss,market,pharmaceutical) [inferred]
(leaders,loss,maritide) [inferred]
(leaders,loss) [inferred]
(leaders,loss,novo_nordisk) [inferred]
(loss,market,novo_nordisk) [inferred]
(longer-lasting,loss,maritide) [inferred]
(longer-lasting,loss,novo_nordisk) [inferred]
(loss,market,once-daily) [inferred]
(loss,market,treatments) [inferred]

WIP - Back to HLA

Meanwhile, investors are eager to see new data on Pfizer's once-daily obesity pill around the middle of the year, which will determine the company's fate in the weight loss drug market. ...
High Level Abstractions:

(loss,market,company)
Inferred entity relationships (9)
(company,loss,once-daily) [inferred]
(loss,market,novo_nordisk) [inferred]
(company,loss,twice-a-day) [inferred]
(company,loss,maritide) [inferred]
(loss,market,once-daily) [inferred]
(loss,market,pharmaceutical) [inferred]
(company,loss,treatments) [inferred]
(loss,market,treatments) [inferred]
(company,loss,shots) [inferred]

WIP - Back to HLA

Amgen, one of the nation's biggest pharmaceutical companies, can also produce drugs at scale - a huge edge over smaller biotech companies that lack a large manufacturing footprint. ...
High Level Abstractions:

(loss,market,manufacturing)
Inferred entity relationships (3)
(loss,manufacturing,maritide) [inferred]
(loss,manufacturing,treatments) [inferred]
(loss,manufacturing,phipps) [inferred]

WIP - Back to HLA

He added that fewer doses could help patients stick to the treatment and maintain weight loss.. . "Even if you do have some nausea for the day, just once a quarter versus once a week I think that's huge for getting more patients to stay on," said Phipps ...
High Level Abstractions:

(loss,nausea)
Inferred entity relationships (2)
(loss,nausea,phipps) [inferred]
(loss,nausea,treatments) [inferred]

WIP - Back to HLA

Other companies - like and partners Boehringer Ingelheim and Zealand Pharma - are among those that are making progress on their own treatments. Novo Nordisk and Eli Lilly are also working on new weight loss drugs. ...
High Level Abstractions:

(loss,zealand_pharma)

WIP - Back to HLA

Viking will likely conduct another phase two trial that could last six to nine months, the company's CEO Brian Lian said during an investor call in March. Viking's treatment likely won't reach the market until 2029 or later, Jefferies analyst Akash Tewari wrote in a note that same month ...
High Level Abstractions:

(market,company,viking)
(market,company,nine)
(market,company,investor)
Inferred entity relationships (9)
(company,market,novo_nordisk) [inferred]
(company,market,treatments) [inferred]
(company,market,once-daily) [inferred]
(company,market,viking) [inferred]
(company,market,twice-a-day) [inferred]
(market,viking) [inferred]
(market,nine) [inferred]
(company,market,nine) [inferred]
(company,market,rebound) [inferred]

WIP - Back to HLA

The company has not provided an estimated launch date for its obesity injection. In a research note published Thursday, JPMorgan analyst Chris Schott estimated it will hit the market in 2028. ...
High Level Abstractions:

(company,analyst)
(market,company,analyst)
Inferred entity relationships (9)
(analyst,company) [inferred]
(company,market,novo_nordisk) [inferred]
(company,market,treatments) [inferred]
(company,market,nine) [inferred]
(company,market,once-daily) [inferred]
(company,market,viking) [inferred]
(company,market,twice-a-day) [inferred]
(company,market,rebound) [inferred]
(analyst,company,market) [inferred]

WIP - Back to HLA

Viking will likely conduct another phase two trial that could last six to nine months, the company's CEO Brian Lian said during an investor call in March. Viking's treatment likely won't reach the market until 2029 or later, Jefferies analyst Akash Tewari wrote in a note that same month. ...
High Level Abstractions:

(market,viking)
(market,company,jefferies)
(market,company,analyst)
(market,nine)
Inferred entity relationships (8)
(analyst,company) [inferred]
(company,market,novo_nordisk) [inferred]
(company,market,treatments) [inferred]
(company,market,once-daily) [inferred]
(company,market,viking) [inferred]
(company,market,twice-a-day) [inferred]
(company,market,nine) [inferred]
(company,market,rebound) [inferred]

WIP - Back to HLA

Pfizer could have another chance to enter the market if it acquires a smaller obesity drugmaker. But for now, dealmaking appears unlikely as the company works to rebound from the decline of its Covid business last year. ...
High Level Abstractions:

(market,company,rebound)
(market,rebound)
Inferred entity relationships (7)
(company,market,novo_nordisk) [inferred]
(company,market,treatments) [inferred]
(market,rebound) [inferred]
(company,market,nine) [inferred]
(company,market,once-daily) [inferred]
(company,market,viking) [inferred]
(company,market,twice-a-day) [inferred]

WIP - Back to HLA

The company has not provided an estimated launch date for its obesity injection. In a research note published Thursday, JPMorgan analyst Chris Schott estimated it will hit the market in 2028. . . Amgen appears to have a competitive edge ...
High Level Abstractions:

(market,analyst)

WIP - Back to HLA

As the company proceeds with the trials needed to bring its experimental obesity injection to the market in the coming years, it could see a few advantages.. . Amgen's drug, MariTide, is taken less frequently than Novo Nordisk's Wegovy and Eli Lilly's Zepbound, and may cause longer-lasting weight loss than the market leaders'injections ...
High Level Abstractions:

(market,novo_nordisk,eli_lilly,maritide)
(market,novo_nordisk,maritide)
Inferred entity relationships (1)
(maritide,market,novo_nordisk) [inferred]

WIP - Back to HLA

As the company proceeds with the trials needed to bring its experimental obesity injection to the market in the coming years, it could see a few advantages. ...
High Level Abstractions:

(market,novo_nordisk,eli_lilly,company)
(market,novo_nordisk,company)
Inferred entity relationships (6)
(company,market,treatments) [inferred]
(company,market,nine) [inferred]
(company,market,once-daily) [inferred]
(company,market,viking) [inferred]
(company,market,twice-a-day) [inferred]
(company,market,rebound) [inferred]

WIP - Back to HLA

Phipps said he's confident that patients can take MariTide even less frequently, such as once a quarter, to maintain the weight loss they saw after starting the drug ...
High Level Abstractions:

(company,loss,maritide)
Inferred entity relationships (10)
(company,loss,once-daily) [inferred]
(company,loss,twice-a-day) [inferred]
(loss,maritide,shots) [inferred]
(loss,maritide,treatments) [inferred]
(company,loss,market) [inferred]
(company,loss,treatments) [inferred]
(loss,maritide,market) [inferred]
(loss,maritide,phipps) [inferred]
(company,loss,shots) [inferred]
(loss,maritide,novo_nordisk) [inferred]

WIP - Back to HLA

That leaves room for new entrants in a segment expected to grow to $100 billion by the end of the decade.. . While Amgen is in a strong position, it will take years for MariTide to reach patients. The company has not provided an estimated launch date for its obesity injection ...
High Level Abstractions:

(company,maritide)

WIP - Back to HLA

They added that the company's drug can also stick around in the body for much longer than current therapies.. . Phipps said he's confident that patients can take MariTide even less frequently, such as once a quarter, to maintain the weight loss they saw after starting the drug ...
High Level Abstractions:

(company,maritide)
(company,therapies)

WIP - Back to HLA

Those who received weekly doses of the treatment lost up to 13.1% of their weight compared to patients who received a placebo after 13 weeks. . . Viking will likely conduct another phase two trial that could last six to nine months, the company's CEO Brian Lian said during an investor call in March ...
High Level Abstractions:

(company,viking)

WIP - Back to HLA

Other companies - like and partners Boehringer Ingelheim and Zealand Pharma - are among those that are making progress on their own treatments. ...
High Level Abstractions:

(company,treatments,zealand_pharma)

WIP - Back to HLA

Other companies - like and partners Boehringer Ingelheim and Zealand Pharma - are among those that are making progress on their own treatments ...
High Level Abstractions:

(company,treatments,boehringer_ingelheim)
Inferred entity relationships (1)
(company,treatments,zealand_pharma) [inferred]

WIP - Back to HLA

Eli Lilly is also developing an oral drug called orforglipron, which targets GLP-1. The company is slated to release late-stage trial data on the pill and retatrutide in 2025. . . Boehringer Ingelheim, Zealand Pharma injection. ...
High Level Abstractions:

(company,retatrutide)
Inferred entity relationships (1)
(company,retatrutide,targets) [inferred]

Semantics Relevance

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss ...